Keyphrases
Colorectal Cancer
100%
Chemotherapy
68%
Metastatic Colorectal Cancer (mCRC)
41%
Epidermal Growth Factor Receptor
39%
Paclitaxel
38%
Hormone-sensitive Prostate Cancer
38%
Docetaxel Chemotherapy
38%
Consensus Conference
38%
Alcohol Dehydrogenase
38%
Radiosurgery
38%
Tumor
37%
Primary Tumor
33%
N-cadherin
30%
Metastasis
30%
Estramustine
29%
Soft Tissue
28%
Docetaxel
28%
Liver Metastasis
26%
Prostate-specific Antigen Doubling Time
25%
Lymphadenectomy
23%
Prostate-specific Antigen
23%
Gastric Cancer
23%
Metastatic Pancreatic Cancer
23%
KRAS mutation
23%
Stage II Colon Cancer
23%
Colon Cancer
22%
Randomized Double-blind
21%
Metastatic Disease
21%
Phase I Clinical Trial
21%
Confidence Interval
20%
Combination Chemotherapy
19%
Thymus
19%
Specific Pattern
19%
Poor Prognosis
19%
Gastric Adenocarcinoma
19%
Thymic Enlargement
19%
Expression Variance
19%
Lymph Node
19%
Methylation
19%
Metastatic Adrenocortical Carcinoma
19%
RAS Status
19%
Olaparib
19%
Health-related Quality of Life
19%
Epistaxis
19%
Cancer Tissue
19%
Anti-EGFR Antibody
19%
Carboplatin
19%
Pathological Use
19%
Vidutolimod
19%
Localized Prostate Cancer
19%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
78%
Chemotherapy
76%
Neoplasm
70%
Metastatic Colorectal Cancer
45%
Epidermal Growth Factor Receptor
42%
Clinical Trial
40%
Paclitaxel
38%
Pancreas Cancer
38%
Docetaxel
38%
Recurrent Disease
38%
Vasopressin
38%
Diseases
33%
Nerve Cell Adhesion Molecule
30%
Primary Tumor
28%
Colon Carcinoma
27%
Liver Metastasis
23%
Estramustine
22%
Ipilimumab
19%
Nivolumab
19%
Rash
19%
Androgen
19%
Doxycycline
19%
Skin Toxicity
19%
Solid Malignant Neoplasm
19%
Castration Resistant Prostate Cancer
19%
Epistaxis
19%
Carboplatin
19%
Epidermal Growth Factor Receptor Kinase Inhibitor
19%
Olaparib
19%
Prostate Cancer
19%
Clinical Study
19%
microRNA
19%
Adrenal Cortex Carcinoma
19%
Intraductal Carcinoma
19%
Acetone
19%
Systemic Treatment
15%
Malignant Neoplasm
13%
Placebo
13%
Morphine
13%
Progression Free Survival
12%
Prostate Specific Antigen
9%
Acute Toxicity
9%
Adverse Event
9%
Recurrence Risk
8%
Cetuximab
8%
Panitumumab
8%
Volume of Distribution
7%
Maximum Tolerated Dose
7%
Hydrocortisone
7%
Monoclonal Antibody
6%
Medicine and Dentistry
Colorectal Carcinoma
76%
Diseases
63%
Prostate Cancer
38%
Gastrectomy
38%
Metastatic Carcinoma
38%
Recurrent Disease
38%
Neoplasm
36%
Lymph Node
35%
Pancreas Cancer
26%
Primary Tumor
26%
Androgen
23%
Docetaxel
23%
Epidermal Growth Factor Receptor
23%
Radiation Therapy
23%
Colon Carcinoma
23%
Retroperitoneal Lymph Node Dissection
22%
Abdominal Cancer
20%
Rebound
19%
Quality of Life
19%
Stomach Adenocarcinoma
19%
Prostate Specific Antigen
19%
Receptor Expression
19%
Gastrointestinal Cancer
19%
Celiac Plexus
19%
Olaparib
19%
Thymus
19%
Medicine
19%
BRCA Mutation
19%
Clinical Trial
19%
Radiosurgery
19%
microRNA
19%
Oncotype DX
19%
Colon
19%
Intraductal Carcinoma
19%
Germ Cell
19%
Cancer
15%
Acetone
15%
Arm
14%
Clinical Stage
14%
Placebo
13%
Numeric Rating Scale
11%
Prostatectomy
9%
Gleason Score
9%
Health Care
9%
Recurrence Risk
8%
Estramustine
8%
Systemic Therapy
8%
Patient Characteristics
8%
Liver Metastasis
8%
Quadrantectomy
7%